What Pandemic Effect? US FDA’s 2021 Approval Class Is Off To Strong Start With 60+ Novel Candidates

 
• By Bridget Silverman

Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.

High corn crops on a row
The US FDA may have a bumper crop of new drug approvals this year.

More from Approvals

More from Product Reviews